Ashvattha Therapeutics website screenshot

Ashvattha Therapeutics

Ashvattha Therapeutics is a clinical-stage biopharmaceutical company developing a new class of precision nanomedicines built on hydroxyl dendrimer therapeutics (HDTs), a platform exclusively licensed from Johns Hopkins University. Hydroxyl dendrimers traverse tissue barriers such as the blood-retinal and blood-brain barrier and are selectively taken up by activated cells in regions of inflammation, allowing known small-molecule drugs to be delivered intracellularly to diseased tissue with sustained effect and reduced off-target exposure. The company is advancing programs across ophthalmology, neurology, and inflammatory disease, led by migaldendranib (MGB), a first-in-class subcutaneously administered nanomedicine in Phase 2 development for diabetic macular edema and neovascular age-related macular degeneration, plus hydroxyl dendrimer PET imaging tracers such as [18F]OP-801. Founded by Jeffrey L. Cleland, Kannan Rangaramanujam, and Sujatha Kannan. Ashvattha publishes no public developer program, API, or machine-readable interface.

Ashvattha Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Nanomedicine.

Ashvattha Therapeutics’ developer surface includes engineering blog and 13 more developer resources.

6.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-25 · rubric v0.14.0
0 APIs
CompanyBiotechnologyPharmaceuticalsLife SciencesNanomedicineDrug DevelopmentClinical TrialsOphthalmologyNeurologyHealth

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-25 · rubric v0.14.0
Composite quality — 6.7/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.4 / 17
Access Clarity 1.8 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 1.9 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Delegated User Identity 0 / 6
Protected Resource Metadata 0 / 5
Registration Without a Human 0 / 6
Agentic Commerce Surface 0 / 5
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/ashvattha-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Resources

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

Access & Security 1

Authentication, authorization, and security posture

Operate 1

Status, limits, changes, and where to get help

Commercial 1

Pricing, plans, and the legal terms of use

Company 6

The organization behind the API

Other 4

Properties that don't map to a standard resource type

Source (apis.yml)

apis.yml Raw ↑
aid: ashvattha-therapeutics
name: Ashvattha Therapeutics
description: Ashvattha Therapeutics is a clinical-stage biopharmaceutical company developing a new class of precision nanomedicines
  built on hydroxyl dendrimer therapeutics (HDTs), a platform exclusively licensed from Johns Hopkins University. Hydroxyl
  dendrimers traverse tissue barriers such as the blood-retinal and blood-brain barrier and are selectively taken up by activated
  cells in regions of inflammation, allowing known small-molecule drugs to be delivered intracellularly to diseased tissue
  with sustained effect and reduced off-target exposure. The company is advancing programs across ophthalmology, neurology,
  and inflammatory disease, led by migaldendranib (MGB), a first-in-class subcutaneously administered nanomedicine in Phase
  2 development for diabetic macular edema and neovascular age-related macular degeneration, plus hydroxyl dendrimer PET imaging
  tracers such as [18F]OP-801. Founded by Jeffrey L. Cleland, Kannan Rangaramanujam, and Sujatha Kannan. Ashvattha publishes
  no public developer program, API, or machine-readable interface.
url: https://raw.githubusercontent.com/api-evangelist/ashvattha-therapeutics/refs/heads/main/apis.yml
image: https://avttx.com/wp-content/uploads/2019/05/logo.png
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-07-31'
modified: '2026-07-31'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Nanomedicine
- Drug Development
- Clinical Trials
- Ophthalmology
- Neurology
- Health
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-31'
  status: minimal
  artifacts_added: 3
  pass: local-v1
common:
- type: DomainSecurity
  url: security/ashvattha-therapeutics-domain-security.yml
- type: LLMsTxt
  url: llms/ashvattha-therapeutics-llms.txt
- type: Website
  url: https://avttx.com/
- type: About
  url: https://avttx.com/about/
- type: Technology
  url: https://avttx.com/technology/
- type: Pipeline
  url: https://avttx.com/pipeline/
- type: Blog
  name: News
  url: https://avttx.com/news/
- type: BlogRSS
  name: News RSS
  url: https://avttx.com/feed/
- type: Resources
  url: https://avttx.com/resources/
- type: Careers
  url: https://avttx.com/careers/
- type: Contact
  url: https://avttx.com/contact/
- type: PrivacyPolicy
  url: https://avttx.com/privacy-policy/
- type: LinkedIn
  url: https://www.linkedin.com/company/ashvattha-therapeutics-inc
- type: SecondaryMarket
  name: Forge Global listing
  url: https://forgeglobal.com/ashvattha-therapeutics_stock/

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this
  • find_providersBrowse and filter every provider in the catalog.
  • get_provider_artifactsEvery artifact this provider publishes, grouped by type.
  • get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
  • get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
  • get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
  • get_provider_ratingPRO — composite, band, trend and facet scores.
  • apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
  • resolveTurn a domain, URL or GitHub org into the provider it belongs to.
  • find_cohortsEvery scored population of providers in the catalog.
All 92 tools

Call it yourself

curl for this page
This provider
curl "https://apis.io/api/v1/providers/ashvattha-therapeutics"
All providers
curl "https://apis.io/api/v1/providers?limit=25"
Every operation they expose
curl "https://apis.io/api/v1/providers/ashvattha-therapeutics/operations?limit=25"
How their score was established
curl "https://apis.io/api/v1/providers/ashvattha-therapeutics/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no email required.

A second provider on the same verified email joins the account you already have.